The conservative management of high risk bladder transitional cell carcinoma T1G3;IL TRATTAMENTO CONSERVATIVO NEL CARCINOMA TRANSIZIONALE AD ALTO RISCHIO (T1G3)

Archivio Italiano di Urologia e Andrologia

Volumn 68, Issue 1, 1996, Pages 21-24

  Catanzaro, F ^a   Torelli, F ^a   Catanzaro, M ^a   Cappellano, F ^a   Pizzoccaro, M ^a   Baruffi, M ^a   Sironi, D ^a   Pozzoli, G L ^a  

^a Ospedale di Circolo   (Italy)

Author keywords

BCG; doxorubicin; T1G3

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN;

BLADDER CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; FOLLOW UP; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MORTALITY; REGIONAL PERFUSION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; TIME FACTORS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0029872911     PISSN: 11208538     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)